# The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome

**Authors:** Hongying Kuang, Yuwei Duan, Dan Li, Yanwen Xu, Wenxia Ai, Wei Li, Ying Wang, Sha Liu, Mushan Li, Xiaoqiu Liu, Manqi Shao

PMC · DOI: 10.1371/journal.pone.0235404 · 2020-08-12

## TL;DR

This study explores how inflammatory cytokines and berberine affect insulin signaling in women with polycystic ovary syndrome (PCOS), finding that berberine may improve insulin sensitivity.

## Contribution

The study identifies specific inflammatory cytokines linked to PCOS and demonstrates berberine's potential to modulate insulin signaling pathways.

## Key findings

- PCOS patients had significantly higher levels of IL-17a, IL-1Ra, and IL-6 compared to non-PCOS patients.
- Berberine reduced mTOR mRNA and increased IRS-1 mRNA in PCOS granulosa cells.
- Elevated inflammatory cytokines disrupt AMH correlations and contribute to insulin resistance in PCOS.

## Abstract

To study the role of selected serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome (PCOS).

Selected serum inflammatory cytokines were analyzed in the particle cells, which were interfered by berberine, from 78 infertile women who were to be treated with In Vitro Fertilization (IVF) /Intracytoplasmic Sperm Injection-Embryo Transfer (icsi-et). Among them, 49 patients had PCOS infertility, and 29 were non-PCOS patients whose infertility resulted from fallopian tube and male factors. The elisa method was used to detect the changes in the expression levels of inflammatory factors in the cells. The correlations between the serum inflammatory cytokine expression levels and the corresponding clinical hormones were analyzed. The changes in the expression (mRNA and protein) levels of the serum inflammatory cytokines were studied by real-time quantitative PCR and protein printing. Fluorescence microscope and flow cytometry were used to detect the glucose uptake capacity of ovarian granulosa cells in PCOS patients under the action of insulin after berberine.

In the PCOS group, IL-17a (P = 0.001), IL-1Ra (P<0.0001), and IL-6 (P = 0.035) were significantly higher than those in the non-PCOS group. In the non-PCOS group, AMH level was negatively correlated with inflammatory cytokines IL-17a (r = -0.819;P = 0.004), IL-1a (r = -0.716;P = 0.0.02), IL-1b (r = -0.678;P = 0.031), IL-2 (r = -0.765;P = 0.01), and IL-8 (r = -0.705;P = 0.023). However, in the PCOS group, AMH levels were not significantly correlated with the levels of the examined inflammatory cytokines. Berberine significantly reduced the expression level of mTOR mRNA (P = 0.001), and increased the expression level of IRS-1 mRNA (P = 0.009) in the PCOS granule cells.

In this study, we find that the elevated levels of serum inflammatory factors IL-17a, IL-1Ra, and IL-6 cause women to be in a subclinical inflammatory state for a long time. Abnormal changes in inflammatory factors alter their original negative correlations with AMH levels, thereby weakening the metabolism of glycolipids, promoting insulin resistance, destroying the normal ovulation and fertilization system of women, leading to polycystic ovary syndrome characterized by menstrual thinning and abnormal ovulation. Berberine can improve the sensitivity of insulin by regulating the signal pathway of insulin receptor substrate-1 (IRS-1) and mammalian target of rapamycin (mTOR) in PCOS patients and achieve a therapeutic effect of treating PCOS.

## Linked entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605], IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554], IL6 (interleukin 6) [NCBI Gene 3569], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], IRS1 (insulin receptor substrate 1) [NCBI Gene 3667]
- **Chemicals:** berberine (PubChem CID 2353)
- **Diseases:** polycystic ovary syndrome (MONDO:0008487)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, SOCS3 (suppressor of cytokine signaling 3) [NCBI Gene 9021] {aka ATOD4, CIS3, Cish3, SOCS-3, SSI-3, SSI3}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, RPS6 (ribosomal protein S6) [NCBI Gene 6194] {aka S6, eS6}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, CAT (catalase) [NCBI Gene 847], CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, RBP4 (retinol binding protein 4) [NCBI Gene 5950] {aka MCOPCB10, RDCCAS}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}
- **Diseases:** hyperandrogenism (MESH:D017588), irregular menstruation (MESH:D008599), chronic inflammation (MESH:D007249), obesity (MESH:D009765), insulin resistance (MESH:D007333), infertility (MESH:D007246), organic diseases of heart, lung, (MESH:D008171), Oligomenorrhea (MESH:D009839), 21 hydroxylase deficiency (MESH:C535979), atresia (MESH:D018633), congenital adrenal hyperplasia (MESH:D000312), mental diseases (MESH:D008607), Amenorrhea (MESH:D000568), Ovarian Ovulation Disorder (MESH:D010049), diarrhea (MESH:D003967), fungal infections (MESH:D009181), metabolic syndrome (MESH:D024821), autoimmune diseases (MESH:D001327), hyperprolactinemia (MESH:D006966), endocrine disease (MESH:D004700), developmental disorders (MESH:D002658), anovulation (MESH:D000858), follicular blockade (MESH:D005497), metabolic diseases (MESH:D008659), IR (MESH:C537629), tumor (MESH:D009369), hyperlipidemia (MESH:D006949), anxiety (MESH:D001007), PCOS (MESH:D011085), depression (MESH:D003866), thyroid dysfunction (MESH:D013959), ovarian polycystic ovary formation (MESH:D013577), androgen excess (MESH:D014770), polycystic changes (MESH:D007690), impaired glucose tolerance (MESH:D018149), Cushing syndrome (MESH:D003480), inflammatory cytokines (MESH:D000080424), ACC (MESH:D004476), reproduction disfunction (MESH:D060737), hirsute acne (MESH:D006628), diabetes (MESH:D003920), bacterial (MESH:D001424), endocrinopathy (MESH:C567425), deterioration in quality of life (MESH:D003643)
- **Chemicals:** sugar (MESH:D000073893), polyacrylamide (MESH:C016679), lipid (MESH:D008055), blood glucose (MESH:D001786), ROS (MESH:D017382), SYBR Green (MESH:C098022), BBR (MESH:D001599), Chinese herbal medicine (-), steroid hormones (MESH:D013256), Trizol (MESH:C411644), 2-NBDG (MESH:C098340), E2 (MESH:D004958), glycolipid (MESH:D006017), dhea (MESH:D003687), glucose (MESH:D005947), PVDF (MESH:C024865),  (MESH:D007378),  (MESH:D007328),  (MESH:D054304),  (MESH:D000893)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Coptis chinensis (species) [taxon 261450]
- **Cell lines:** TK6 — Homo sapiens (Human), Hereditary spherocytosis, Transformed cell line (CVCL_0561), A 549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), WI-38 — Homo sapiens (Human), Finite cell line (CVCL_0579)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC7423132/full.md

---
Source: https://tomesphere.com/paper/PMC7423132